← Back to Search

Monoclonal Antibodies

BRII-196/BRII-198 for Coronavirus (TICO Trial)

Phase 3
Waitlist Available
Led By Prof. Jens Lundgren
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

TICO Trial Summary

This trial looks at the safety and effectiveness of different drugs in treating COVID-19 in hospitalized patients.

Eligible Conditions
  • Coronavirus

TICO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time from randomization to sustained recovery
Secondary outcome measures
All-cause mortality
Change in SARS-CoV-2 neutralizing antibody levels
Change in neutralizing antibody levels
+13 more

TICO Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ACTIV-3 Drug plus SOCExperimental Treatment7 Interventions
Participants in this study will be randomized to receive one of the ACTIV-3 drug treatments plus Standard of Care (SOC) or placebo plus SOC
Group II: Placebo plus SOCPlacebo Group2 Interventions
The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Remdesivir
2020
Completed Phase 3
~21440
BRII-196/BRII-198
2020
Completed Phase 3
~2760
LY3819253
2020
Completed Phase 3
~6430
PF-07304814
2020
Completed Phase 3
~2800
MP0420
2021
Completed Phase 3
~3240
VIR-7831
2020
Completed Phase 3
~4880
AZD7442
2022
Completed Phase 3
~11880

Find a Location

Who is running the clinical trial?

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNETWORK
99 Previous Clinical Trials
70,883 Total Patients Enrolled
Cardiothoracic Surgical Trials NetworkOTHER
8 Previous Clinical Trials
3,571 Total Patients Enrolled
Prevention and Early Treatment of Acute Lung InjuryOTHER
8 Previous Clinical Trials
3,571 Total Patients Enrolled
~570 spots leftby Jun 2025